# Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1

> **NCT02724358** · NA · COMPLETED · sponsor: **Eastern Hepatobiliary Surgery Hospital** · enrollment: 320 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- TACE
- Notch1
- Rg3

## Interventions

- **PROCEDURE:** TACE
- **DRUG:** Rg3
- **OTHER:** TACE + Rg3
- **PROCEDURE:** protective therapy

## Key facts

- **NCT ID:** NCT02724358
- **Lead sponsor:** Eastern Hepatobiliary Surgery Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-12
- **Final completion:** 2015-12
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2016-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02724358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02724358, "Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02724358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*